Conflict of Interest:
VBI
B.A. is an employee of Foundation Medicine and Roche. P.Y.W. receives research support from Astra Zeneca/Medimmune, Beigene, Black Diamond, Celgene, Chimerix, Eli Lily, ERASCA, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics, and VBI Vaccines, and serves on the advisory board of Astra Zeneca, Bayer, Black Diamond, Boehringer Ingelheim, Boston Pharmaceuticals, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Karyopharm, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, VBI Vaccines. A.A. receives research funding from Varian and NH TherAGuIX and is consulting for Novartis and Seagen. F.M. is a cofounder of and has equity in Harbinger Health, has equity in Zephyr AI, and serves as a consultant for Harbinger Health, Zephyr AI, and Red Cell Partners. D.H.-K. is on the scientific Advisory Board of EmpNia, Inc., and Graegis’s Scientific. JD received research support from Novartis and is a consultant for Unum Therapeutics and Amgen. The authors declare that none of these relationships are directly or indirectly related to the content of this manuscript.